Predictive ability of laboratory indices for liver fibrosis in patients with chronic hepatitis C after the eradication of hepatitis C virus

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Tachi, Yoshihiko ^a   Hirai, Takanori ^a   Toyoda, Hidenori ^b   Tada, Toshifumi ^b   Hayashi, Kazuhiko ^c   Honda, Takashi ^c   Ishigami, Masatoshi ^c   Goto, Hidemi ^c   Kumada, Takashi ^b  

^a KOMAKI CITY HOSPITAL   (Japan)

^b OGAKI MUNICIPAL HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; INTERFERON; PEGINTERFERON; RIBAVIRIN;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE PLATELET RATIO INDEX; CHRONIC HEPATITIS C; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME ACTIVITY; FEMALE; FIB 4 INDEX; FORNS INDEX; HEPATITIS; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; NONHUMAN; PREDICTIVE VALUE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOCYTE; VIRAL CLEARANCE; AGED; BIOPSY; BLOOD; COMPLICATION; FOLLOW UP; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY;

AGED; BIOPSY; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 84941888269     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133515     Document Type: Article

References (37)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750. PMID: 10072408.
2. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compemsated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472. PMID: 9024300.
3. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-2100. PMID: 14697814.
4. Singal AG, Volk ML, Jensen D, Di AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8: 280-288. doi: 10.1016/j.cgh.2009.11.018 PMID: 19948249.
5. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-881. PMID: 9382365.
6. Shiffman ML, Hofmann CM, Thompson EB, Ferreira-Gonzalez A, Contos MJ, Koshy A, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997; 26: 780-785. PMID: 9303513.
7. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-524. PMID: 10744587.
8. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-1130. PMID: 10094956.
9. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998; 129: 94-99. PMID: 9669992.
10. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174-181. PMID: 10428733.
11. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998; 27: 1394-1402. PMID: 9581697.
12. Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: A prospective multicenter study. J Hepatol 2013; 58: 495-501. doi: 10.1016/j.jhep. 2012.10.017 PMID: 23099187.
13. Iwasaki Y, Takaguchi K, Ikeda H, Makino Y, Araki Y, Ando M, et al. Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy. Liver Int 2004; 24: 603-610. PMID: 15566511.
14. Tokita H, Fukui H, Tanaka A, Kamitsukasa H, Yagura M, Harada H, et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol 2005; 20: 752-758. PMID: 15853990.
15. Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 2005; 40: 148-156. PMID: 15770398.
16. Makiyama A, Itoh Y, Kasahara A, Imai Y, Kawata S, Yoshioka K, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004; 101: 1616-1622. PMID: 15378504.
17. Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013; 57: 230-236. doi: 10.1093/cid/cit234 PMID: 23616492.
18. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526. PMID: 12883497.
19. Sterling RK, Lissen E, Clumeck N, Sola R, Cassia Correa M, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325. PMID: 16729309.
20. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest. Hepatolofy 2007; 46: 32-36.
21. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986- 992. PMID: 12297848.
22. Koda M, Matsunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007; 45: 297-306. PMID: 17256741.
23. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet M-C, Konate A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42: 1373-1381. PMID: 16317693.
24. Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (Fibro Test) and activity (Acti Test) in patients with chronic liver diseases. Comp Hepatol 2002; 1: 3. PMID: 12537583.
25. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: An accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-1873. PMID: 16055434.
26. Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pitis R, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006; 44: 686-693. PMID: 16490278.
27. Guzelbulut F, Akkan Centinkaya Z, Sezikli M, Yasar B, Ozkara S, Kurdas Ovunc AO. AST-platelet ratio index, Forns index and FIB-4 index in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. Turk J Gastroenterol 2011; 22: 279-285. PMID: 21805418.
28. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20. PMID: 8020885.
29. Lok AS, Gardiner DF, Lawitz E, Matrorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-224. doi: 10.1056/NEJMoa1104430 PMID: 22256805.
30. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 34-44. doi: 10.1056/NEJMoa1208953 PMID: 23281974.
31. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887. doi: 10.1056/NEJMoa1214853 PMID: 23607594.
32. Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Mullhaupt B, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-639. doi: 10.1056/NEJMoa1213557 PMID: 23944300.
33. Tachi Y, Hirai T, Miyata A, Ohara K, Iida T, Ishizu Y, et al. Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response. Hepatol Res 2015; 45: 238-246. doi: 10.1111/hepr.12331 PMID: 24655233.
34. Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, et al. Role of liver biopsy in management of chronic hepatitis C. Hepatology 2002; 36: S161-S172. PMID: 12407590.
35. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500. PMID: 11172192.
36. Degasperi E, Grassi E, Fraquelli M, Aghemo A, D'Ambrosio R, Colombo M. Low accuracy of non-invasive tests for assessing residual cirrhosis in hepatitis C patients with a sustained virological response. J Hepatol 2014; 60: S418-S419.
37. Toyoda H, Kumada T, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, et al. Risk factors for HCC development in non-cirrhotic patients with sustained virologic response for chronic HCV infection. J Gastroenterol Hepatol (in press).